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Abstract
Parkinson’s disease (PD) is a common neurodegenerative condition in which abnormalities in protein homeostasis, or
proteostasis, may lead to accumulation of the protein a-synuclein (a-syn). Mutations within or multiplications of the gene
encoding a-syn are known to cause genetic forms of PD and polymorphisms in the gene are recently established risk factors
for idiopathic PD. a-syn is a major component of Lewy bodies, the intracellular proteinaceous inclusions which are
pathological hallmarks of most forms of PD. Recent evidence demonstrates that a-syn can self associate into soluble
oligomeric species and implicates these a-syn oligomers in cell death. We have previously shown that carboxyl terminus of
Hsp70-interacting protein (CHIP), a co-chaperone molecule with E3 ubiquitin ligase activity, may reduce the levels of toxic a-
syn oligomers. Here we demonstrate that a-syn is ubiquitinylated by CHIP both in vitro and in cells. We find that the
products from ubiquitinylation by CHIP include both monoubiquitinylated and polyubiquitinylated forms of a-syn. We also
demonstrate that CHIP and a-syn exist within a protein complex with the co-chaperone bcl-2-associated athanogene 5
(BAG5) in brain. The interaction of CHIP with BAG5 is mediated by Hsp70 which binds to the tetratricopeptide repeat
domain of CHIP and the BAG domains of BAG5. The Hsp70-mediated association of BAG5 with CHIP results in inhibition of
CHIP E3 ubiquitin ligase activity and subsequently reduces a-syn ubiquitinylation. Furthermore, we use a luciferase-based
protein-fragment complementation assay of a-syn oligomerization to investigate regulation of a-syn oligomers by CHIP in
living cells. We demonstrate that BAG5 mitigates the ability of CHIP to reduce a-syn oligomerization and that non-
ubiquitinylated a-syn has an increased propensity for oligomerization. Thus, our results identify CHIP as an E3 ubiquitin
ligase of a-syn and suggest a novel function for BAG5 as a modulator of CHIP E3 ubiquitin ligase activity with implications
for CHIP-mediated regulation of a-syn oligomerization.
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Introduction
Parkinson’s disease (PD) is a movement disorder affecting
approximately three percent of the population over the age of
sixty-five and is second only to Alzheimer’s disease as the most
common neurodegenerative disease [1]. Loss of dopaminergic
neurons in the substantia nigra pars compacta is one of the
neuropathological hallmarks of all forms of PD. In addition,
idiopathic PD and most familial forms of PD are characterized by
the presence of intracellular protein aggregates, known as Lewy
bodies and Lewy neurites, within the surviving nigral neurons. a-
Synuclein (a-syn) is a major component of these protein inclusions
[2,3]. Genetic evidence supports a role for a-syn in the
pathogenesis of PD. In particular, missense mutations (A53T,
A30P, and E46K) in the a-syn gene (PARK1), as well as
duplications and triplications of the locus containing the a-syn
gene (initially PARK4), are associated with rare familial forms of
PD [4]. Furthermore, polymorphisms in the gene have recently
been identified as risk factors for idiopathic PD [5,6]. a-syn as well
as other proteins within Lewy bodies are frequently ubiquitiny-
lated [2,3]. These inclusions also contain members of the heat
shock protein (Hsp) family such as Hsp70 [7–9], and co-chaperone
molecules including carboxyl terminus of Hsp70-interacting
protein (CHIP) [10] and bcl-2-associated athanogene 5 (BAG5)
[11].
Although a-syn-containing protein aggregates are a neuropath-
ological feature of PD, there is considerable debate regarding the
role of protein aggregates in neurodegenerative disorders including
PD. Recent evidence suggests that a-syn not only forms insoluble
deposits within Lewy bodies but that a-syn monomers can also self
associate into soluble higher-order structures such as oligomers.
These soluble oligomeric species of a-syn may confer significant
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and co-chaperones [14,18–20]. We have previously demonstrated
that the co-chaperone CHIP associates with a-syn and reduces the
levels of toxic a-syn oligomers via both lysosomal and proteasomal
pathways [10,14].
CHIP contains an amino terminal tetratricopeptide repeat
(TPR) domain which mediates its interaction with both Hsp70 and
Hsp90 [21,22] and a carboxyl terminal U-box domain which
confers E3 ubiquitin ligase activity [23,24]. A number of substrates
of CHIP-mediated E3 ubiquitin ligase have been identified
including Hsp70 [25], glucocorticoid receptor [22], ErbB2 [26],
neuronal nitric-oxide synthase (nNOS) [27], the mutant androgen
receptor associated with spinal and bulbar muscular atrophy [28],
and more recently leucine-rich repeat kinase-2 (LRRK2) [29,30].
Members of the BAG domain-containing family of proteins have
been shown to interact with CHIP and regulate its function
[23,31–33]. There are currently six known human BAG family
members (BAG1 to BAG6) which functionally interact with
diverse binding partners and regulate important processes such as
cell division and cell death. We have previously shown that BAG5
may enhance dopaminergic neuronal death in models of PD [11].
Here we identify BAG5 as a negative regulator of CHIP. We find
that a-syn is a novel substrate of CHIP and demonstrate that
BAG5 both inhibits a-syn ubiquitinylation by CHIP and mitigates
CHIP-mediated reduction of a-syn oligomers.
Results
CHIP Reduces a-Synuclein Oligomerization
We have recently developed a highly sensitive bioluminescent
protein-fragment complementation assay (PCA) to study the
regulation of a-syn oligomerization [16,19,34]. In this strategy,
full-length human a-syn was subcloned upstream from the
optimized amino terminal (amino acids 1–93) or carboxyl terminal
(amino acids 94–185) fragments of Gaussia princeps luciferase to
generate the expression constructs referred to as syn-luc1 and syn-
luc2, respectively (Fig. 1A). Reconstitution of a complete luciferase
molecule from the fragments can occur upon a-syn-a-syn
interactions in cells and thus luciferase activity provides a
surrogate measure of a-syn oligomerization [16,19]. In human
H4 neuroglioma cells, transient transfection of syn-luc1 or syn-luc2
individually did not demonstrate any luciferase activity over
transfection with the control vector pcDNA whereas co-expression
of syn-luc1 and syn-luc2 showed a significant increase in
measurable luciferase activity relative to baseline (Fig. 1B). We
found that co-expression of CHIP with syn-luc1 and syn-luc2
resulted in a 25% reduction in luciferase activity compared with
control vector (Fig. 1C). Thus, we inferred that CHIP decreases
the levels of a-syn oligomers.
Nevertheless, it is possible that CHIP with its co-chaperone
function might reduce luciferase activity by directly altering the
folding or stability of luciferase independent of a-syn. This
possibility was tested in experiments using constructs of the amino
terminal fragment without a-syn, referred to as linker-luc1, or of
the full-length Gaussia princeps luciferase (Fig. 1A). Co-expression of
CHIP with full-length luciferase did not result in a reduction in
luciferase activity compared with control vector (Fig. 1D).
Furthermore, we found that the low level of protein complemen-
tation that occurred with co-expression of linker-luc1 and syn-luc2
was not significantly altered by overexpression of CHIP (Fig. 1E).
The results from these experiments demonstrated that CHIP does
not modulate the luciferase activity of full-length luciferase or of
reconstituted luciferase in the absence of a-syn-a-syn interactions,
indicating that the reduction of luciferase activity in the PCAs is
due to the effect of CHIP on a-syn oligomers.
CHIP Mediates Ubiquitinylation of a-Synuclein
Given that CHIP regulates a-syn oligomerization and is also
known to associate in a complex with a-syn [14], we hypothesized
that a-syn may be a substrate of CHIP-mediated E3 ubiquitin
ligase activity. To explore this hypothesis, we first performed a
series of immunoprecipitation experiments from lysates of H4 cells
co-transfected with HA-tagged ubiquitin (HA-Ub) and syn-luc1 or
syn-luc2. The tags of either syn-luc1 (Fig. 2A) or syn-luc2 (data not
shown) allowed for immunoprecipitation from transfected cell
lysates with an anti-luciferase (anti-luc) antibody. We performed
immunoprecipitation under strongly denaturing conditions to
prevent the possible co-immunoprecipitation of ubiquitinylated
proteins other than a-syn. Using this approach, we found three
major bands on Western blot which were immunoreactive with
anti-HA antibodies (Fig. 2A). To identify which, if any, of these
immunoprecipitated bands corresponded to ubiquitinylated forms
of a-syn rather than the luciferase fragment, we designed a mutant
of human full-length a-syn which was resistant to ubiquitinylation
by mutating all potential canonical ubiquitinylation sites in a-syn.
To generate this mutant a-syn, we substituted the lysine residues
within a-syn with arginine, which is similar in size and charge to
lysine. This mutant gene was then subcloned upstream from the
amino terminal or carboxyl terminal fragments of luciferase to
generate synKR-luc1 and synKR-luc2, respectively. These
constructs were identical to syn-luc1 and syn-luc2 with the
exception of the lysine-to-arginine substitutions within a-syn only.
The mutant synKR-luc1, like wild-type syn-luc1, could be
immunoprecipitated by anti-luc antibodies and was detected on
Western blot with an anti-a-syn antibody (H3C) which binds to an
epitope that contains no lysines within the carboxyl terminal
region of a-syn. We discovered that one of the three bands from
syn-luc1 immunoprecipitates detected by anti-HA antibodies was
not present in synKR-luc1 immunoprecipitates, indicating that
this band corresponds to a ubiquitinylated form of a-syn in cells
(Fig. 2B). In contrast, the other two bands represent either
ubiquitinylation of lysine residues within the luciferase fragment
tag only or amino terminal ubiquitinylation of a-syn [35]. Given
that a-syn is not a likely candidate for amino terminal
ubiquitinylation because it is acetylated at the amino terminus
[36,37], the latter is a less likely possibility.
Using densitometric analysis of relative grey values in multiple
experiments (n=3), we found that ubiquitinylation of a-syn was
increased by approximately 50% with co-expression of CHIP
(Fig. 2C). Similar results were found when the immunoprecipitates
were probed with anti-a-syn antibodies at longer exposure
(Fig. 2D) or when a-syn was immunoprecipitated by anti-a-syn
instead of anti-luc antibodies (Fig. 2E).
CHIP E3 Activity is Sufficient for Ubiquitinylation of
a-Synuclein
A given substrate may be ubiquitinylated by any one or more of
the multiple E3 ubiquitin ligases expressed within cells. In addition
to its E3 activity, CHIP has also been shown to have E4-like
activity in that it positively regulates other E3s such as parkin [38].
To test whether CHIP E3 activity is sufficient for ubiquitinylation
of a-syn, we utilized a reconstituted in vitro system in which we
combined purified recombinant CHIP, in the absence of any other
E3s, with purified ubiquitin, the E1 Ube1, and the E2 UbcH5b.
Like many E3 ubiquitin ligases, CHIP is known to ubiquitinylate
itself in vitro [24]. We first confirmed CHIP E3 ligase activity in our
system by testing for auto-ubiquitinylation of CHIP, as well as
CHIP Ubiquitinates a-Synuclein
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e14695Figure 1. CHIP overexpression decreases a-syn oligomer levels. (A) Schematic of the constructs used in the bioluminescent PCA with Gaussia
princeps luciferase (luc) to assay for a-syn oligomerization. Fragments of luc were cloned downstream of full-length human a-syn to generate the
expression constructs referred to as syn-luc1 and syn-luc2. Reconstitution of luc from the fragments can occur upon a-syn-a-syn interactions in cells
and thus luciferase activity provides a surrogate measure of a-syn oligomerization [16,19]. Control experiments were performed with a luc fragment
without a-syn (linker-luc1) and with full-length luciferase. (B) Luciferase activity was measured from H4 cells transfected with pcDNA control, syn-luc1
or syn-luc2 alone, or co-transfected with syn-luc1 and syn-luc2. Bars correspond to mean (6 S.D.) luciferase activity measured in relative luciferase
units (RLU). *P,0.05, ANOVA with Tukey Honest Significance Difference (HSD) post hoc test versus pcDNA control. Results are representative of three
experiments performed in triplicate. Protein expression of syn-luc1 and syn-luc2 was analyzed by Western blot with anti-a-syn antibodies (inset).
Molecular weight markers are shown in kDa. (C) Luciferase activity was measured from H4 cells co-transfected with syn-luc1 and syn-luc2 plus either
pcDNA control or CHIP. Bars correspond to mean (6 S.D.) luciferase activity normalized to measures obtained for co-transfection of syn-luc1 and syn-
luc2 with pcDNA. *P,0.01, t-test versus pcDNA control. Results are representative of three experiments performed in triplicate. (D) Luciferase activity
was measured from cells co-transfected with full-length luciferase plus either pcDNA control or CHIP. There was no statistically significant difference
between these two conditions (P.0.05, t-test versus pcDNA control). (E) PCAs were performed with the indicated constructs. There was no
statistically significant difference between luciferase activity in cells co-expressing linker-luc1 and syn-luc2 with or without CHIP (P.0.05, t-test).
Protein expression was examined by Western blot with anti-luc antibodies (inset).
doi:10.1371/journal.pone.0014695.g001
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e14695Figure 2. CHIP mediates ubiquitinylation of a-syn in cells. (A) Immunoprecipitations with anti-luc were performed from lysates of H4 cells
transfected with HA-Ub, syn-luc1, and control vector or myc-CHIP as indicated. Immunoprecipitates were sequentially probed with anti-HA (upper)
and anti-a-syn (middle) antibodies. Five percent of lysates used for immunoprecipitation was loaded as input and probed with anti-myc or anti-a-syn
antibodies (lower). The middle band represents monoubiquitinylated a-syn (UB-a-syn). The asterisks (*) indicate immunoprecipitated bands that
remain detectable by the anti-HA antibody following the substitution of all lysines within the a-syn sequence (see (B)). Molecular weight markers are
indicated on left in kDa. (B) Immunoprecipitations with anti-luc were performed from lysates of H4 cells transfected with syn-luc1, synKR-luc1, HA-Ub,
and myc-CHIP as indicated. Immunoprecipitated proteins were probed with anti-a-syn antibodies (H3C) which recognizes both syn-luc1 and synKR-
luc1. The asterisks (*) correspond with the same bands indicated as such in (A). (C) Densitometric quantification of the band representing
monoubiquitinylated a-syn when co-transfected with a control vector or myc-CHIP was performed from three independent experiments, one of
which is represented in (A). Bars correspond to mean (6 S.D.) gray value normalized to measures obtained for co-transfection of syn-luc1 and HA-Ub
with control vector. *P,0.05, t-test versus control vector. (D) Proteins immunoprecipitated with anti-luc were probed with anti-a-syn antibodies (Syn-
1) with a short or long exposure to film. The asterisks (*) correspond with the same bands seen in (A) and (B). (E) Immunoprecipitations with anti-a-
syn were performed from lysates of H4 cells transfected with syn-luc1 and HA-Ub with control vector or myc-CHIP. Immunoprecipitated proteins
were sequentially probed with anti-HA (upper) and anti-luc (lower) antibodies. The asterisks (*) correspond to the bands as indicated in (A), (B), and
(D). Results are representative of three experiments.
doi:10.1371/journal.pone.0014695.g002
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(Fig. 3A). Given that the overexpression of CHIP enhanced
ubiquitinylation of syn-luc1 in cells, we next determined whether
untagged wild-type a-syn was a substrate of CHIP by testing
purified wild-type a-syn in this in vitro system. We detected by
Western blot a molecular weight band of approximately 24 kDa in
size recognized by both anti-a-syn and anti-ubiquitin antibodies
(Fig. 3B). Higher molecular weight ubiquitinylated a-syn species
were also recognized by these antibodies. CHIP E3 activity was
verified in these assays by CHIP auto-ubiquitinylation (Fig. 3B).
To test the specificity of a-syn ubiquitinylation by CHIP in our
system, we examined two other E3 ubiquitin ligases, HDM2 [39]
and MuRF1 [40], which utilize the same UbcH5 family of E2s as
CHIP to mediate the ubiquitinylation of substrate proteins. Using
HDM2 or MuRF1 with the E2s UbcH5b or UbcH5a, each E3
was enzymatically active as demonstrated by their ability to auto-
ubiquitinylate. However, we found that neither HDM2 nor
MuRF1 mediated the ubiquitinylation of a-syn in vitro (Fig. 3C).
Taken together, these results imply that untagged wild-type a-syn
is a substrate of CHIP and that CHIP E3 ubiquitin ligase activity is
sufficient for a-syn ubiquitinylation.
a-Synuclein is Monoubiquitinylated by CHIP
One of the ubiquitinylated forms of a-syn identified in the in vitro
ubiquitinylation assays with CHIP was approximately 24 kDa in
size (Fig. 3B and 3C) which is compatible with a-syn linked to
monoubiquitin. To investigate the possibility that a-syn may be
monoubiquitinylated in cells, we utilized a mutant of ubiquitin that
lacks lysine residues (HA-UbKO) thus preventing polyubiquitiny-
lation, but not monoubiquitinylation, of substrates. We found that
with co-transfection of HA-Ub KO, in place of wild-type
ubiquitin, the same band we identified as corresponding to
ubiquitinylated a-syn was present (Fig. 4). Thus, CHIP may both
polyubiquitinylate and monoubiquitinylate a-syn.
CHIP Interacts with the Co-Chaperone BAG5
The identity of molecules responsible for regulating CHIP-
mediated ubiquitinylation of a-syn and reduction of a-syn
oligomerization by CHIP is unknown. A molecular candidate
for modulating CHIP function is the BAG domain-containing co-
chaperone BAG5. The activity of CHIP has been shown to be
regulated by members of the BAG family, including BAG1 [23]
and BAG2 [32,33,41] which each associate with CHIP and
modulate CHIP E3 ubiquitin ligase function. We have previously
discovered that BAG5, a BAG family member which is unique in
that it contains multiple BAG domains, enhances a-syn-mediated
toxicity in cultured cells and dopaminergic neuronal death in
models of PD [11]. The E3 ubiquitin ligase parkin is negatively
regulated through an interaction with BAG5 [11]. Therefore, we
tested whether CHIP may also interact with BAG5.
We expressed CHIP with or without FLAG-tagged BAG5
(FLAG-BAG5) in H4 neuroglioma cells and found that CHIP co-
immunoprecipitated with FLAG-BAG5 but not with anti-FLAG
antibodies in the absence of FLAG-BAG5 (Fig. 5A). Given that we
have previously shown that BAG5 interacts with Hsp70 [11], the
same membranes were re-probed with anti-Hsp70 antibodies
which confirmed the presence of endogenous Hsp70 in the
immunoprecipitates with FLAG-BAG5 and its absence in the
immunoprecipitates lacking FLAG-BAG5. We next performed
pull down assays (PDAs) with GST fusion proteins using lysates
from H4 cells transiently transfected with full-length CHIP. We
demonstrated that a purified recombinant GST fusion protein of
BAG5 (GST-BAG5) pulled down full-length CHIP (Fig. 5B). In
contrast, CHIP was not pulled down by GST alone, confirming
that the specificity of the interaction is conferred by BAG5 and not
the GST tag. CHIP was also not pulled down by a GST fusion
protein of a mutant of BAG5 called BAG5 DARA (see below).
Hsp70 Mediates the Association between CHIP and BAG5
To map which domain of CHIP may mediate the interaction
with BAG5, we performed PDAs using lysates from H4 cells
individually transfected with CHIP deletion constructs lacking the
U-box domain (CHIP DU) or the TPR domain (CHIP DTPR).
We found that GST-BAG5 pulled down CHIP DU but not CHIP
DTPR (Fig. 6A). PDAs with GST alone served to control for the
GST tag of GST-BAG5 and demonstrated no interaction with
either CHIP DU or CHIP DTPR. To ensure that the purified
recombinant BAG5 protein was in its native conformation and
hence would have interacted with BAG domain ligands, we
probed the proteins pulled down by GST-BAG5 for endogenous
Hsp70 (Fig. 6A), which is known to directly bind to the BAG
domains of BAG5 [11,42].
The TPR domain of CHIP is known to mediate an interaction
with Hsp70 [43]. Given that its deletion prevented the association
of CHIP with BAG5, we hypothesized that Hsp70 may mediate
the interaction between CHIP and BAG5. We have previously
characterized a mutant of BAG5 called BAG5 DARA which does
not interact with Hsp70 but retains the ability to dimerize with
itself, to heterodimerize with wild-type BAG5, and to interact with
other BAG5 binding partners [11]. To explore the possibility that
Hsp70 mediates the CHIP-BAG5 interaction, we used a GST
fusion protein of BAG5 DARA (GST-BAG5 DARA) in PDAs. We
found that GST-BAG5 DARA, which did not pull down
endogenous Hsp70 (Fig. 5B), also did not pull down full-length
CHIP (Fig. 5B) or the CHIP deletion mutants (Fig. 6A).
To further test our hypothesis, we performed PDAs in an
isolated in vitro system using purified recombinant CHIP and
Hsp70 proteins. We found that a GST fusion protein of BAG1
(GST-BAG1) pulled down CHIP in the absence of Hsp70 (Fig. 6B).
BAG1 is a BAG domain-containing protein previously shown to
directly interact with CHIP but to also have enhanced binding to
CHIP in the presence of Hsp70 [23]. In contrast to GST-BAG1,
we found that like GST alone, neither GST-BAG5 nor GST-
BAG5 DARA pulled down significant amounts of CHIP in the
absence of Hsp70. However, with the addition of Hsp70, GST-
BAG5 pulled down CHIP whereas GST alone or GST-BAG5
DARA did not (Fig. 6B). From these results, we conclude that
CHIP indirectly associates with BAG5. The association between
CHIP and BAG5 is mediated by Hsp70 which is known to bind to
the TPR domain of CHIP and the BAG domains of BAG5.
BAG5 Inhibits the Ubiquitinylation of a-Synuclein by CHIP
To begin to investigate the consequences of the CHIP-BAG5
association on CHIP function, we examined whether BAG5 affects
the E3 ubiquitin ligase activity of CHIP. We found that addition of
purified recombinant GST-BAG5 to in vitro ubiquitinylation assays
with CHIP and a-syn resulted in a significant and dose-dependent
reduction in a-syn monoubiquitinylation compared to the addition
of equimolar amounts of GST (Fig. 7A). We also found a dose-
dependent decrease in ubiquitinylation of Hsp70 with the addition
of GST-BAG5. The levels of auto-ubiquitinylation of CHIP were
unaltered regardless of the addition of GST or GST-BAG5
suggesting that the effect of BAG5 on CHIP-mediated ubiquiti-
nylation may be specific for both a-syn and Hsp70. We next tested
the effect of BAG5 on CHIP-mediated ubiquitinylation of a-syn in
cells by performing immunoprecipitation experiments from lysates
of H4 cells co-transfected with syn-luc1, myc-CHIP, HA-Ub, and
FLAG-BAG5 (Fig. 7B). Co-expression of BAG5 with CHIP
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ubiquitinylation levels of a-syn compared to empty control vector
(Fig. 7C). Overexpression of BAG5 did not alter the levels of a-syn
or CHIP (Fig. 7D). Together these findings indicate that BAG5
inhibits CHIP-mediated ubiquitinylation of a-syn.
BAG5 Mitigates CHIP-Mediated Reduction of a-Synuclein
Oligomers
To explore the potential consequences of ubiquitinylation of a-
syn by CHIP, we performed a series of experiments using the
luciferase-based PCA to assess a-syn oligomerization. We first
determined the effect of targeted reduction of CHIP activity on the
levels of a-syn oligomers. To this end, we generated a stable H4
cell line in which CHIP protein expression was knocked down
utilizing short-hairpin RNA (shRNA). We also made a control cell
line which was stably transfected with a non-targeting shRNA
vector that activates the RNA-induced silencing complex (RISC)
and RNA interference (RNAi) pathway. We confirmed knock-
down of CHIP protein expression by Western blot in the CHIP
shRNA stable cell line relative to the control cell line (Fig. 8A).
There were no differences in the expression of endogenous a-syn
Figure 3. Wild-type a-syn is a substrate of CHIP E3 ubiquitin ligase activity in vitro. (A) In vitro ubiquitinylation assays were performed by
incubating purified recombinant proteins of the E1 Ube1, the E2 UbcH5b, and the CHIP substrate Hsp70 with and without purified ubiquitin or CHIP.
Ubiquitinylation of CHIP and Hsp70 was determined by Western blot using anti-CHIP (upper) and anti-Hsp70 (middle) antibodies, respectively. The
high molecular weight smears represented ubiquitinylated ((UB)n) forms of CHIP and Hsp70. The purified recombinant proteins used in the assay
were stained with Ponceau S (lower). Similar results were found in more than five experiments. Molecular weight markers are shown on left in kDa. (B)
In vitro ubiquitinylation assays were performed by incubating purified recombinant human untagged wild-type a-syn with ubiquitin, Ube1, UbcH5b,
CHIP, and Mg-ATP as indicated. Ubiquitinylation of a-syn (UB-a-syn and (UB)n-a-syn) was determined by Western blot using anti-a-syn (upper) and
anti-ubiquitin (middle) antibodies. The asterisk (*) indicates a non-specific band. Ubiquitinylation of CHIP was detected with anti-CHIP antibodies
(lower). Results are representative of more than five experiments. Molecular weight markers are shown in kDa. (C) In vitro ubiquitinylation assays were
performed with a-syn, Ube1, and either the E2 UbcH5a or UbcH5b plus His-tagged CHIP, HDM2, or MuRF1 or in the absence of an E3 ubiquitin ligase.
Experiments were performed without and with ubiquitin as indicated. Ubiquitinylation of a-syn and the E3 ubiquitin ligases was detected with anti-a-
syn and anti-His antibodies, respectively. The asterisk (*) indicates a non-specific band. Molecular weight markers in kDa are indicated.
doi:10.1371/journal.pone.0014695.g003
Figure 4. CHIP monoubiquitinylates a-syn. Immunoprecipitations
with anti-luc were performed from lysates of H4 cells transfected with
syn-luc1, synKR-luc1, HA-Ub WT, HA-Ub KO, and myc-CHIP as indicated.
Immunoprecipitates were sequentially probed with anti-HA (upper) and
anti-a-syn (Syn-1) (middle) antibodies. For the anti-a-syn blots, short
exposure times were used to allow for the comparison of amount of a-
syn immunoprecipitated in each of the conditions. Ubiquitinylated
forms of a-syn are not detectable by Syn-1 at these shorter exposure
times (see Figure 2D). Five percent of lysates used for immunoprecip-
itation was loaded as input and probed with anti-HA antibodies which
recognize HA-ubiquitin monomers (UB) and proteins with covalently
attached HA-ubiquitin (lower). The middle band represents mono-
ubiquitinylated a-syn (UB-a-syn). The asterisks (*) correspond with
immunoprecipitated bands that remain detectable by the anti-HA
antibody following the substitution of all lysines within the a-syn
sequence. These are the same bands seen in Figure 2. Similar results
were found in each of three experiments.
doi:10.1371/journal.pone.0014695.g004
Figure 5. CHIP forms a protein complex with BAG5. (A)
Immunoprecipitations with anti-FLAG antibodies were performed from
lysates of H4 cells transfected with CHIP with or without FLAG-BAG5 as
indicated. Immunoprecipitates were sequentially probed with anti-CHIP
(upper), anti-Hsp70 (middle), and anti-FLAG (lower) antibodies. Ten
percent of lysates used for immunoprecipitation was loaded as input.
The upper CHIP band corresponds to monoubiquitinylated CHIP [62].
Molecular weight markers are shown on right. Similar results were
found in three separate experiments. (B) PDAs were performed using
lysates of H4 cells transfected with CHIP. Proteins that associated with
GST alone, GST-BAG5, or GST-BAG5 DARA were probed with anti-CHIP
(upper) and anti-Hsp70 (middle) antibodies. Input was 10% of lysates
used for PDAs. The presence of equal amounts of GST fusion proteins
was confirmed by Ponceau S staining of the membranes (lower).
Molecular weight markers are indicated on right. Results are
representative of four independent experiments.
doi:10.1371/journal.pone.0014695.g005
CHIP Ubiquitinates a-Synuclein
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e14695or Hsp70. We co-transfected the CHIP shRNA stable cell line or
control cell line with syn-luc1 and syn-luc2. We found a significant
increase of approximately 35% in measured luciferase activity in
cells with a targeted reduction of CHIP expression relative to
control cells (Fig. 8B). Similar results were obtained in three
separate CHIP shRNA stable cell lines (data not shown). To
confirm the specificity of the observed shRNA effect on CHIP, we
utilized a myc-tagged CHIP expression vector which is resistant to
the targeting shRNA (Fig. 8C). Co-transfecting syn-luc1 and syn-
luc2 with myc-CHIP in the CHIP knockdown cell line resulted in
a significant decrease in measured luciferase activity (Fig. 8D).
Consistent with CHIP activity mediating reduction of a-syn
oligomers, expression of myc-CHIP rescued the effect of CHIP
shRNA knockdown and resulted in a larger decrease of a-syn
oligomers in the CHIP knockdown cell line than in cells with
baseline endogenous CHIP expression (see Fig. 1C).
Next we performed luciferase-based PCAs using the mutant a-
syn constructs which have all lysine residues in a-syn substituted
with arginine and consequently cannot be ubiquitinylated by
CHIP. We found that co-expression of the mutants synKR-luc1
and synKR-luc2 resulted in a 16% increase in luciferase activity
compared to co-expression of syn-luc1 and syn-luc2 (Fig. 8E),
accounting for approximately 50% of the effect seen with the
knockdown of CHIP activity (see Fig. 8B). Thus, knockdown of
CHIP function increases the levels of oligomeric a-syn species and
a-syn mutants that are not ubiquitinylated have a greater
propensity to oligomerize.
Since BAG5 inhibits CHIP-mediated ubiquitinylation of a-syn,
it is predicted that BAG5 would preclude the reduction of a-syn
oligomers by CHIP. To test this prediction, we first performed
PDAs to examine for protein-protein interactions and found that
syn-luc1 and syn-luc2 may associate with the CHIP-Hsp70-BAG5
complex (Fig. 9A). Next, we found that in luciferase-based PCAs
co-expression of BAG5 with CHIP blocked approximately 50% of
the CHIP-mediated reduction of a-syn oligomers (Fig. 9B).
To examine whether an interaction may occur between
endogenously expressed a-syn, CHIP, and BAG5, we performed
co-immunoprecipitations using mouse brain homogenates and
found that these proteins form a complex (Fig. 9C). Furthermore,
we investigated whether these proteins may co-localize in neurons
within human brain. We performed immunohistochemistry for a-
syn, CHIP, and BAG5 on substantia nigra pars compacta samples
from two patients with a neuropathological diagnosis of dementia
with Lewy bodies (DLB), a neurodegenerative disease with
histopathology similar to PD. CHIP immunoreactivity co-localized
with both a-syn and BAG5 within a-syn-positive intracytoplasmic
inclusions suggestive of Lewy bodies in the substantia nigra of both
patients (Fig. 9D). Colocalization was also observed in the
cytoplasm of neurons containing a-syn-positive inclusions as well
as neurons lacking inclusions. Thus, we demonstrate an associa-
tion of endogenous a-syn, CHIP, and BAG5. Taking our data
together, we conclude that the CHIP-BAG5 interaction negatively
regulates CHIP-mediated reduction of a-syn oligomerization.
Discussion
There is growing evidence that a subpopulation of a-syn may be
covalently modified by ubiquitinylation and that ubiquitinylated a-
syn is present in Lewy bodies [44–46]. However, identification of
the key enzymes involved and understanding of the functional
consequences of a-syn ubiquitinylation remain less clear. Here we
found that CHIP overexpression enhanced ubiquitinylation of a-
syn in cells. To provide evidence that our finding was not a result
of the action of other E3s or was not simply due to the previously
demonstrated E4-like function of CHIP, we utilized an isolated in
vitro system to test CHIP E3 activity. This approach had the added
advantage of allowing us to study untagged wild type human a-
syn. We found that CHIP, but not the other E3 ubiquitin ligases
HDM2 or MuRF1, ubiquitinylates a-syn. Hence we show that a-
syn is a substrate of the ubiquitin ligase CHIP and that CHIP E3
Figure 6. Hsp70 is required for the association between CHIP and BAG5. (A) PDAs with GST fusion proteins using lysates of H4 cells
transfected with the CHIP deletion constructs CHIP DU and CHIP DTPR are shown. The blots were probed with anti-CHIP (upper) and anti-Hsp70
(lower) antibodies. The inputs shown are 10% of total lysates used in each assay. Molecular weight markers are indicated. Results are representative of
three independent experiments. (B) PDAs were performed using GST fusion proteins and purified recombinant CHIP with or without Hsp70 as
indicated. Proteins that associated with GST alone, GST-BAG5, GST-BAG5 DARA, or GST-BAG1 were probed with anti-CHIP (upper) and anti-Hsp70
(middle) antibodies. Input was 10% of proteins used for PDAs. The presence of equal amounts of GST fusion proteins was confirmed by Ponceau S
staining (lower). Molecular weight markers are indicated. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0014695.g006
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studies will be necessary to elucidate whether CHIP’s putative E4
activity also plays a role in enhancing a-syn ubiquitinylation in vivo.
a-syn is a major component of Lewy bodies and these
pathological protein inclusions are frequently immunoreactive
for ubiquitin [3]. Protein extracts from the brains of patients with
Lewy body pathology have been reported to contain monoubi-
quitinylated or multiubiquitinylated a-syn species in which a single
ubiquitin moiety is attached to one or more lysine residues,
respectively [36,45,46]. In the present study, we found that a-syn
ubiquitinylated by CHIP in vitro migrated at a size of 24 kDa,
which is consistent with the calculated size for a monoubiquiti-
nylated form of a-syn, as well as at higher molecular weights. With
polyubiquitinylation of a protein, ubiquitins are linked to each
other by isopeptide bonds between lysine and carboxyl terminal
glycine residues to form polyubiquitin chains. Monoubiquitinyla-
tion, but not polyubiquitinylation, can occur if all lysine residues
are mutated in ubiquitin (Ub KO). We found that in cells, a-syn
could be ubiquitinylated with wild-type ubiquitin or with mutant
Ub KO by CHIP. Thus, the products from CHIP-mediated
ubiquitinylation of a-syn include not only polyubiquitinylated but
also monoubiquitinylated species.
Monoubiquitinylated a-syn was also identified in H4 cells
without overexpression of CHIP. It is possible that this finding was
partly a result of the appreciable endogenous expression of CHIP
in these cells. Alternatively, functional redundancy of E3 ubiquitin
ligases has been observed in CHIP
2/2 mouse embryonic
fibroblasts in which established CHIP substrates, such as nNOS,
Figure 7. BAG5 inhibits CHIP-mediated ubiquitinylation of a-syn in vitro and in cells. (A) In vitro ubiquitinylation assays were performed
with increasing amounts of GST or GST-BAG5 as indicated. Ubiquitinylation was determined by Western blot using anti-a-syn, anti-CHIP, or anti-
Hsp70 antibodies. GST fusion proteins were stained with Ponceau S. Similar results were found in three experiments. (B) Immunoprecipitations with
anti-luc were performed from lysates of H4 cells transfected with syn-luc1, myc-CHIP, HA-Ub, and FLAG-BAG5 as shown. Ubiquitinylation of a-syn was
detected using anti-HA antibodies (upper). The arrow indicates the monoubiquitinylated form of a-syn (UB-a-syn). Immunoprecipitation of equivalent
amounts of a-syn was confirmed by probing with anti-a-syn antibodies (lower). The asterisk (*) indicates cross-reactivity of the secondary antibody
with the immunoglobulin light chain. (C) Quantification by densitometric analysis of the UB-a-syn band with co-transfection of a control vector or
FLAG-BAG5 from three independent experiments, one of which is represented in (B). Bars shown correspond to mean (6S.D.) gray value normalized
to measures obtained for the control vector. *P,0.05, t-test versus control vector. (D) Protein expression levels of a-syn and CHIP with and without
BAG5 overexpression was assessed by Western blot. Actin was used as a loading control.
doi:10.1371/journal.pone.0014695.g007
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seven in absentia homolog (SIAH) has previously been found to
monoubiquitinylate a-syn [48,49]. Knockdown of endogenous
SIAH does not completely abolish a-syn ubiquitinylation [48]
consistent with a possible contribution of several E3 ligases,
including CHIP, to the monoubiquitinylation of a-syn.
Figure 8. Targeted knockdown of CHIP or absence of a-syn ubiquitinylation increases oligomerization of a-syn. (A) Knockdown of
CHIP protein expression in the CHIP shRNA stable cell line versus a control shRNA cell line was confirmed by Western blot. The membrane was
sequentially probed with anti-CHIP, anti-Hsp70, and anti-a-syn antibodies. GAPDH was used as a loading control. (B) Luciferase activity was measured
from CHIP shRNA or control shRNA stable cell lines transiently co-transfected with syn-luc1 and syn-luc2. Bars correspond to mean (6 S.D.) luciferase
activity normalized to measures obtained for control shRNA cells co-transfected with syn-luc1 and syn-luc2. *P,0.01, t-test versus control shRNA.
Results are representative of three experiments performed in triplicate in three different stable cell line clones. Protein expression of syn-luc1 and syn-
luc2 was analyzed by Western blot with anti-luc antibodies (inset). (C) CHIP shRNA stable cell line was transiently co-transfected with syn-luc1 and
syn-luc2 plus either pcDNA as control or myc-CHIP. Protein expression of myc-CHIP was confirmed by Western blot with anti-myc antibodies and anti-
CHIP antibodies (data not shown). GAPDH was used as a loading control. (D) Luciferase activity was measured from cells described in (C). Bars
correspond to mean (6 S.D.) luciferase activity normalized to measures obtained for co-transfection of syn-luc1 and syn-luc2 with pcDNA control.
*P,0.01, t-test versus control. Results are representative of six experiments performed in triplicate. (E) Luciferase activity was measured from H4 cells
transfected with syn-luc1 and syn-luc2 or with synKR-luc1 and synKR-luc2 relative to protein expression by densitometric quantitation. Bars
correspond to mean (6 S.D.) luciferase activity normalized to measures obtained for co-transfection with syn-luc1 and syn-luc2. *P,0.05, t-test versus
syn-luc1+syn-luc2. Protein expression of syn-luc1, syn-luc2, synKR-luc1, and synKR-luc2 was analyzed by Western blot with anti-luc antibodies and
GAPDH was used as a loading control (inset). Results are representative of three experiments performed in triplicate.
doi:10.1371/journal.pone.0014695.g008
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being monoubiquitinylated. However, the consequences of mono-
ubiquitinylation for a substrate protein are continuing to be
defined. Monoubiquitinylation has been implicated in the
targeting of membrane proteins for endocytosis and lysosomal
degradation [50] and in the regulation of protein complex
assembly [51]. Monoubiquitinylation has also been found to act
as a nuclear export signal [52] and to regulate transcription [50].
In contrast to polyubiquitinylation, monoubiquitinylation was
initially thought to not participate in proteasomal degradation.
However, monoubiquitinylation has been recently reported to act
as a signal for targeting Pax3 to the proteasome [53]. The exact
fate of monoubiquitinylated species of a-syn remains elusive.
Whereas monoubiquitinylation of a-syn by SIAH promotes the
formation of large insoluble intracellular aggregates [49], we have
previously demonstrated that CHIP decreases insoluble a-syn
aggregate formation [10]. Here we also found that CHIP reduces
soluble a-syn oligomeric species. Thus there may be differential
consequences of ubiquitinylation of a-syn depending on the
specific E3 ubiquitin ligase.
Accumulating evidence suggests that soluble a-syn oligomers
play an important role in the pathogenesis of genetic and
idiopathic forms of PD [13,15,17]. PCAs provide the distinct
advantage of allowing real time detection and analysis of
oligomeric species of a-syn in live cells [14,16,19]. We have
previously shown that CHIP reduces the amount of a-syn
Figure 9. BAG5 negatively regulates CHIP-mediated reduction of a-syn oligomer levels. (A) PDAs were performed using GST fusion
proteins and lysates from H4 cells transfected with syn-luc1, syn-luc2, CHIP, and Hsp70. Proteins that associated with GST alone or GST-BAG5 were
probed with anti-a-syn (upper), anti-CHIP (middle), and anti-Hsp70 (lower) antibodies. Input was 10% of total lysates used for PDAs. Results are
representative of three independent experiments. (B) Luciferase activity was measured from H4 cells transfected with syn-luc1 and syn-luc2 plus the
vectors indicated on the horizontal axis of the graph. The total DNA used in each condition was equalized using the empty vector pcDNA. Bars
correspond to mean (6s.e.m.) luciferase activity normalized to measures obtained for the co-transfection of syn-luc1 and syn-luc2 with pcDNA as
control (*P,0.05, ANOVA with Tukey HSD post hoc test versus control). Results shown are from four independent experiments performed in
triplicate. (C) Immunoprecipitations with anti-a-syn antibodies or IgG control were performed from mouse brain homogenates. Immunoprecipitates
were sequentially probed with anti-a-syn, anti-CHIP, anti-Hsp70, and anti-BAG5 antibodies as indicated. Ten percent of lysates used for
immunoprecipitation was loaded as input. A longer exposure of the same blot was required to visualize the input for BAG5. The asterisk (*) indicates
cross-reactivity of the secondary antibody with the immunoglobulin heavy chain. Similar results were found in three separate experiments. (D)
Immunohistochemistry for a-syn, BAG5, and CHIP was performed on substantia nigra pars compacta samples from patients with a neuropathological
diagnosis of DLB. a-syn immunoreactivity (green in upper), BAG5 immunoreactivity (green in lower), and CHIP immunoreactivity (red) in neurons and
in a-syn-positive intracytoplasmic inclusions are shown. Co-localization is demonstrated in the merged images (yellow). DAPI staining (blue)
demonstrates nuclear localization. Five to ten percent of nigral neurons contained a-syn-positive intracytoplasmic inclusions. At least ten a-syn-
positive inclusion-containing neurons were visualized in the substantia nigra pars compacta of each of two patients with DLB. All of the visualized a-
syn-positive inclusions were positive for both BAG5 and CHIP.
doi:10.1371/journal.pone.0014695.g009
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fragments [14]. GFP-based PCAs are irreversible which can be
useful to study the formation of stabilized a-syn oligomers [34] but
may be less helpful for the study of the kinetics of oligomer
stability. Using a luciferase-based assay in which oligomerization
of a-syn is transient [34], we found that CHIP mitigated the
accumulation of soluble a-syn oligomers. In contrast, targeted
knockdown of CHIP or blocking a-syn ubiquitinylation by
mutating its lysine residues enhanced a-syn oligomerization. Thus,
we infer that CHIP-mediated ubiquitinylation of a-syn may
contribute, at least in part, to the reduction of a-syn oligomers.
Furthermore we demonstrated that BAG5, which inhibits CHIP-
mediated ubiquitinylation of a-syn in cells and in vitro, mitigates the
effect of CHIP on reducing a-syn oligomers.
Other members of the BAG family of co-chaperone proteins,
including BAG1 [23] and BAG2 [32,33], have been previously
found to interact with and regulate CHIP function. However,
BAG1 and BAG2 have different effects on CHIP. BAG2 has been
demonstrated to inhibit CHIP E3 ubiquitin ligase activity,
resulting in decreased ubiquitinylation of CHIP substrates
including Hsp70, the NBD1-R binding domain of cystic fibrosis
transmembrane conductance regulator (CFTR), and raf-1 [32,33].
BAG2 may inhibit CHIP function by disrupting the interaction
between CHIP and its E2, UbcH5b [32,33]. We found that, like
BAG2, BAG5 inhibits the E3 ubiquitin ligase activity of CHIP.
The mechanism by which BAG5 inhibits CHIP remains to be
elucidated. By contrast, BAG1 has been shown to enhance CHIP-
mediated degradation of the glucocorticoid receptor, a known
substrate of CHIP [23]. In addition to a BAG domain, BAG1
contains a ubiquitin-like domain which may mediate an
interaction with the 26S proteasome [54]. It is postulated that
BAG1 could facilitate proteasomal degradation of CHIP sub-
strates, such as the glucocorticoid receptor, by simultaneously
binding to CHIP and the proteasome [23,54]. Thus, the
differential effect of BAG1 on CHIP function compared to
BAG2 and BAG5 may be conferred by the ubiquitin-like domain
of BAG1. Alternatively, there are inherent structural differences
between the BAG domain of BAG1 and the BAG domains of
BAG2 and BAG5 [42,55–57] which may impart distinct effects on
the regulation of associated E3 ligases such as CHIP.
BAG proteins have been found to regulate other E3 ubiquitin
ligases in addition to CHIP. BAG1 has been previously shown to
interact via its BAG domain with SIAH and inhibit SIAH function
[58]. We have previously demonstrated that BAG5 directly
interacts with and inhibits parkin [11], an E3 ubiquitin ligase
which is mutated in an autosomal recessive form of PD. Thus,
BAG domain-containing co-chaperones may be common regula-
tors of E3 ubiquitin ligases. More recent evidence has shown that
the ratio of the BAG domain-containing proteins BAG1 and
BAG3 may shift protein degradation towards different pathways
[59] and thus regulate proteostasis. We have previously shown that
CHIP can target a-syn for degradation by both proteasomal and
lysosomal pathways [10] and perhaps the ratios of different BAG
domain-containing family members available for interacting with
CHIP, such as BAG1, BAG2, and BAG5, may act as molecular
switches in determining the ultimate fate of CHIP substrates such
as a-syn.
In summary, we have identified a-syn as a novel substrate of
CHIP E3 ubiquitin ligase activity and discovered that CHIP and
a-syn form a protein complex with the co-chaperone BAG5. The
functional significance of the CHIP-BAG5 interaction is the
ubiquitinylation of a-syn by CHIP which may, in part, play a role
in the reduction of a-syn oligomers. Consistent with this, we found
that BAG5 inhibited CHIP-mediated ubiquitinylation of a-syn
and mitigated the ability of CHIP to decrease levels of a-syn
oligomers. Emerging evidence is suggesting that the BAG family of
proteins, in general, may be critical regulators of E3 ubiquitin
ligases. BAG domain-containing proteins in cooperation with
other molecular chaperones, such as CHIP and Hsp70, may
contribute to the triage of misfolded proteins but, in a disease state
like PD, these critical protein handling pathways may become
dysregulated. Thus, therapies which enhance CHIP E3 ubiquitin
ligase activity or inhibit BAG5 function within dopaminergic
neurons and other neuronal populations susceptible to a-syn-
mediated toxicity may decrease cell death and slow the progression
of neurodegeneration in PD.
Materials and Methods
DNA Constructs
The following DNA expression constructs were used: syn-luc1
and syn-luc2 [16,19], linker-luc1 containing amino acids 1 to 93 of
Gaussia princeps luciferase (kindly provided by S. Michnick,
University of Montreal) [34], full-length native Gaussia princeps
luciferase (pUC18 GLuc from Prolume), pcDNA3-CHIP,
pcDNA3-CHIP DU, pcDNA3-CHIP DTPR (kind gifts from C.
Patterson, University of North Carolina School of Medicine) [22],
pcDNA3.1-myc-CHIP [10], pRK5-HA-Ubiquitin-WT and
pRK5-HA-Ubiquitin-KO (Addgene) [60], pDEST-FLAG-BAG5
[11], pcDNA3.1-Hsp70 [8], and pcDNA3.1 (Invitrogen). To
generate the synKR-luc1 and synKR-luc2 constructs, a coding
sequence was designed in which all lysines in human full-length
wild-type a-syn were substituted with arginine using codons to
minimize sequence differences between wild-type and mutant.
The sequence was synthesized and cloned into pDONR (DNA
2.0) and then subcloned into the same vectors used to make the
syn-luc1 and syn-luc2 constructs.
Cell Culture and Transfections
Human H4 neuroglioma cells (ATCC) were maintained in
Opti-MEM media (Invitrogen) supplemented with 10% FBS
(Invitrogen) at 37uC and 5% CO2. Cells were transiently
transfected using SuperFect (Qiagen) according to the manufac-
turer’s instructions. To generate cell lines stably expressing
shRNA, H4 cells were transfected with MISSION shRNA
pLKO.1-puro vectors encoding shRNAs targeting human CHIP
(validated clones NM_005861.1-716s1c1 and NM_005861.1-
479s1c1) or MISSION pLKO.1-puro vector containing a non-
targeting control shRNA (Sigma). Cells were grown in selection
media containing 4 mg/mL puromycin (Sigma) and colonies of
cells demonstrating resistance to puromycin were isolated. The
individual cell lines were maintained in Opti-MEM media
supplemented with 10% FBS and 4 mg/mL puromycin. Protein
expression in these cell lines was assessed by Western blot using
anti-CHIP rabbit polyclonal antibodies (Calbiochem).
Protein Complementation Assay with Gaussia Luciferase
H4 cells were transiently transfected in 6-well plates as
described above. At 24 hr post-transfection, cells were scraped
from each culture well in 1 mL PBS and then 100 mL of cells
were transferred in triplicate to a 96-well plate. Native
coelenterazine (Prolume), a cell permeable substrate of Gaussia
luciferase, was resuspended in methanol to 1 mg/mL and
dispensed per well to a final concentration of 20 mMb ya n
automated plate reader, Wallac 1420 Victor2 (Perkin Elmer).
The bioluminescent signal generated by the luciferase enzyme
was integrated over 2 sec before measurement at 480 nm. Co-
transfection of pSV-b-galactosidase vector (Promega) was used to
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enzyme assay system following the lysis of the remaining cells
with reporter lysis buffer as per the manufacturer’s protocol
(Promega).
Ubiquitinylation Assays
To test for ubiquitinylation in cells, H4 cells were transiently
transfected with DNA expression constructs as indicated. At 24 hr
post-transfection, cells were harvested under denaturing conditions
in buffer containing 50 mM Tris (pH 7.4), 140 mM NaCl, 1%
SDS and sheared with a 27-gauge needle 5 to 6 times. Samples
were boiled for 5 min and then diluted 10-fold with buffer
containing 50 mM Tris (pH 7.4), 140 mM NaCl, 1% Triton X-
100, and protease inhibitor cocktail (Roche). Samples were
centrifuged at 21,0006 g for 2 min. Cell lysates were then
incubated with anti-Gaussia luciferase rabbit polyclonal (Prolume)
or anti-a-syn mouse monoclonal (BD Biosciences) antibodies
overnight at 4uC. Immune complexes were isolated by the
addition of 50 mL of protein A or G Sepharose beads (GE
Healthcare) followed by incubation for 2 to 3 hr at 4uC.
Immunoprecipitates were washed 36 with buffer containing
50 mM Tris (pH 7.4) and 500 mM NaCl, and then analyzed by
SDS-PAGE and Western blot with anti-HA rat monoclonal
(Roche) or anti-a-syn mouse monoclonal antibodies (Syn-1 from
BD Biosciences or H3C, a kind gift from D. Clayton and J.
George, University of Illinois) [61].
For in vitro ubiquitinylation assays, purified recombinant
human a-syn (1.5 mM) from rPeptide was incubated with 1 mM
His-tagged CHIP (Millipore) or HDM2 or MuRF1 (Boston
Biochem), 0.5 mM Hsp70 (Assay Designs), 5 mMU b c H 5 b ,
50 nM Ube1, 10 mM ubiquitin (Boston Biochem), and Mg-ATP
(Boston Biochem) as indicated in 16 ubiquitin conjugation
reaction buffer (Boston Biochem) for 1 hr at 30uC. GST or
GST-BAG5 (0.5 to 4 mM) was included in the assays performed
to test the effect of BAG5 on CHIP E3 activity. Prior to use in
t h e s ea s s a y s ,t h eG S Tf u s i o np r o t e i n sw e r ee l u t e df r o m
glutathione Sepharose beads and dialyzed in PBS using Slide-
A-Lyzer dialysis cassettes (Pierce). Samples from the ubiquiti-
nylation assays were analyzed by SDS-PAGE followed by
Western blot with the following antibodies: anti-ubiquitin rabbit
polyclonal (Dako), anti-a-syn mouse monoclonal (BD Biosci-
ences), anti-CHIP rabbit polyclonal (Calbiochem), anti-Hsp70
rabbit polyclonal (Assay Designs), anti-His mouse monoclonal
(GE Healthcare).
Co-immunoprecipitations
Immunoprecipitation of proteins was performed under non-
denaturing conditions from H4 cell lysates or mouse brain
homogenates. H4 neuroglioma cells were lysed 24 hr after
transfection in modified RIPA buffer (50 mM Tris (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1% Igepal CA-360) with protease
inhibitor cocktail (Roche). Cell lysates were incubated overnight
at 4uC with agarose conjugated anti-FLAG M2 antibodies
(Sigma) and washed according to the manufacturer’s protocol.
Samples were then separated by SDS-PAGE and analyzed by
Western blot. Whole brains from C57BL/6J mice were
homogenized in sucrose buffer (4 mM HEPES (pH 7.3),
0.32 M sucrose) supplemented with protease inhibitors (Roche)
and then centrifuged at 10006gf o r1 5m i na t4 uCf o l l o w e db ya
subsequent centrifugation of the supernatant at 10,0006 gf o r
15 min at 4uC. Homogenates were incubated overnight at 4uC
with anti-a-syn antibodies (BD Biosciences) or control mouse IgG
(Sigma). Immunoprecipitates were incubated with protein G
Sepharose beads (GE Healthcare) for 4 hr at 4uC and then
washed 36 with RIPA buffer supplemented with protease
inhibitors. Samples were then separated by SDS-PAGE and
analyzed by Western blot using HRP-conjugated IgG secondary
antibodies (GE Healthcare) to detect a-syn, CHIP, and Hsp70,
and biotin-conjugated IgG secondary antibodies (Jackson Im-
munoResearch) to detect BAG5.
GST Pull Down Assays
GST fusion constructs (GST, GST-BAG5, GST-BAG5 DARA
[11]) were transformed into E. coli BL21 cells. GST fusion proteins
were affinity purified using glutathione Sepharose beads (GE
Healthcare) according to the manufacturer’s instructions. Equal
amounts of GST fusion proteins coupled to beads were incubated
overnight at 4uC with proteins solubilized from transfected H4
cells lysed in modified RIPA buffer. Beads were then washed 36
with PBS. To test for direct binding between proteins, equal
amounts of GST fusion proteins coupled to beads were incubated
for 2 hr at 4uC with recombinant CHIP (100 ng) (Millipore) with
or without Hsp70 (100 ng) (StressGen) in binding buffer (20 mM
Tris (pH 8.0), 300 mM NaCl, 2 mM EDTA, 2 mM dithiothre-
itol). Samples were then washed 36with binding buffer containing
400 mM NaCl. Samples were separated by SDS-PAGE and
analyzed by Western blot.
Immunohistochemistry
Human midbrain tissue from two subjects with a neuropath-
ological diagnosis of DLB was obtained from the Harvard Brain
Tissue Resource Center. The subjects were females aged 77 and
85 with a post-mortem interval of 5 and 12 hours, respectively.
The tissue was fixed in 4% paraformaldehyde and sectioned as
free floating 40 mm sections. The sections were permeabilized in
0.5% Triton X-100 in TBS (pH 7.4) for 10 min at room
temperature. The sections were then blocked in 3% normal goat
serum (Jackson ImmunoResearch) for 1 hr. Sections were
incubated in blocking solution at 4uC overnight with a
combination of mouse anti-a-syn antibody (dilution 1:250; BD
Bioscience) and rabbit anti-CHIP antibody (dilution 1:200;
Calbiochem), or with a combination of mouse anti-BAG5
antibody (dilution 1:250; Santa Cruz) [11] and rabbit anti-CHIP
antibody (dilution 1:200; Calbiochem). On the following day,
sections were washed three times in TBS, followed by incubation
with secondary antibodies conjugated to AlexFluor488 (dilution
1:500; Invitrogen) or Cy3 (dilution 1:500; Jackson) for 1 hr at
room temperature. Sections were subsequently washed with TBS
and mounted on slides with Vectashield mounting media with
DAPI (Vector Labs). Cells were imaged on an Olympus BX51
microscope with an epifluorescence attachment. To distinguish
positive staining from autofluorescence or non-specific staining,
sections were incubated with no antibodies or with non-immune
sera (mouse IgG and rabbit IgG from Jackson ImmunoResearch)
in place of primary antibodies, respectively. These control sections
were examined with the same intensity setting and exposure times
used for the labelled samples.
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